Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T-cell lymphoma

Marlies Vanden Bempt, Koen Debackere, Sofie Demeyer, Quentin Van Thillo, Nienke Meeuws, Cristina Prieto, Sarah Provost, Nicole Mentens, Kris Jacobs, Olga Gielen, David Nittner, Seishi Ogawa, Keisuke Kataoka, Carlos Graux, Thomas Tousseyn, Jan Cools, Daan Dierickx

Blood (2022) 140 (23): 2463–2476.

https://doi.org/10.1182/blood.2022016428

Published: 2022

Includes: Supplemental data

Journal Articles

Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia

Michael Broux, Cristina Prieto, Sofie Demeyer, Marlies Vanden Bempt, Llucia Alberti-Servera, Inge Lodewijckx, Roel Vandepoel, Nicole Mentens, Olga Gielen, Kris Jacobs, Ellen Geerdens, Carmen Vicente, Charles E. de Bock, Jan Cools

Blood (2019) 134 (16): 1323–1336.

https://doi.org/10.1182/blood.2019000015

Published: 2019

Includes: Supplemental data

Journal Articles

JAK3 Mutants Transform Hematopoietic Cells through JAK1 Activation Causing T-Cell Acute Lymphoblastic Leukemia in a Bone Marrow Transplant Mouse Model

Degryse Sandrine, Charles E de Bock, PhD, Carmen Vicente, PhD, Luk Cox, PhD, Olga Gielen, Nicole Mentens, Kris Jacobs, Ellen Geerdens, Thomas Tousseyn, PhD, Jan Cools, PhD

Blood (2014) 124 (21): 361.

https://doi.org/10.1182/blood.V124.21.361.361

Published: 2014

Journal Articles

Use of Crispr/Cas Genome Editing in Ba/F3 Cells to Generate the Fip1l1-Pdgfra and Nup214-Abl1 Fusion Genes

Marlies Vanden Bempt, Msc, Charles E de Bock, PhD, Nicole Mentens, Olga Gielen, Ellen Geerdens, Sofie Demeyer, PhD, Jan Cools, PhD

Blood (2014) 124 (21): 3575.

https://doi.org/10.1182/blood.V124.21.3575.3575

Published: 2014

Journal Articles

Synergism Between HOXA9 and Mutant JAK3 (M511I) Leads to Rapid Leukemia Development within an in Vivo Murine Bone Marrow Transplant Model

Charles E de Bock, PhD, Sandrine Degryse, Sofie Demeyer, PhD, Bram Sweron, Olga Gielen, Nicole Mentens, Ellen Geerdens, Jan Cools, PhD

Blood (2014) 124 (21): 1078.

https://doi.org/10.1182/blood.V124.21.1078.1078

Published: 2014

Journal Articles

JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model

Sandrine Degryse, Charles E. de Bock, Luk Cox, Sofie Demeyer, Olga Gielen, Nicole Mentens, Kris Jacobs, Ellen Geerdens, Valentina Gianfelici, Gert Hulselmans, Mark Fiers, Stein Aerts, Jules P. Meijerink, Thomas Tousseyn, Jan Cools

Blood (2014) 124 (20): 3092–3100.

https://doi.org/10.1182/blood-2014-04-566687

Published: 2014

Includes: Supplemental data

Journal Articles

PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia

Maria Kleppe, Jean Soulier, Vahid Asnafi, Nicole Mentens, Tekla Hornakova, Laurent Knoops, Stefan Constantinescu, François Sigaux, Jules P. Meijerink, Peter Vandenberghe, Marco Tartaglia, Robin Foa, Elizabeth Macintyre, Torsten Haferlach, Jan Cools

Blood (2011) 117 (26): 7090–7098.

https://doi.org/10.1182/blood-2010-10-314286

Published: 2011

Journal Articles

Deletion of the Protein Tyrosine Phosphatase Gene PTPN2 in T-Cell Acute Lymphoblastic Leukemia.

Maria Kleppe, Idoya Lahortiga, PhD, Tiama El Chaar, Kim De Keersmaecker, PhD, Nicole Mentens, Carlos Graux, MD, PhD, Katrien Van Roosbroeck, Adolfo A. Ferrando, MD, PhD, Anton W Langerak, PhD, Jules P.P. Meijerink, PhD, Francois Sigaux, MD, Torsten Haferlach, MD, Iwona Wlodarska, PhD, Peter Vandenberghe, MD, PhD, Jean Soulier, MD, PhD, Jan Cools, PhD

Blood (2009) 114 (22): 141.

https://doi.org/10.1182/blood.V114.22.141.141

Published: 2009

Journal Articles

Sorafenib Potently Inhibits ETV6-PDGFRβ and FLT3 Mutants, and Shows Activity Against FLT3 Mutants That Are Resistant to Other Small Molecule Inhibitors.

Els Lierman, BSc, Idoya Lahortiga, PhD, Helen Van Miegroet, Nicole Mentens, Peter Marynen, PhD, Jan Cools, PhD

Blood (2006) 108 (11): 1993.

https://doi.org/10.1182/blood.V108.11.1993.1993

Published: 2006

Journal Articles

Oncogenic Properties of the T-ALL Associated EML1-ABL1 and NUP214-ABL1 Fusion Proteins.

Kim De Keersmaecker, Rafael Bernad, Cedric Folens, Nicole Mentens, Peter Marynen, Maarten Fornerod, Jan Cools

Blood (2006) 108 (11): 1830.

https://doi.org/10.1182/blood.V108.11.1830.1830

Published: 2006

Journal Articles

Array-CGH Analysis of T-ALL Patients and Cell Lines.

Idoya Lahortiga, PhD, Carlos Graux, MD, Nicole Mentens, Katrien Van Roosbroeck, Kim De Keersmaecker, Frederic Lambert, MD, Peter Vandenberghe, MD, Iwona Wlodarska, PhD, Guy Froyen, PhD, Maria D. Odero, PhD, MD, Peter Marynen, PhD, Jan Cools, PhD

Blood (2006) 108 (11): 4469.

https://doi.org/10.1182/blood.V108.11.4469.4469

Published: 2006

Journal Articles

Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant

Els Lierman, Cedric Folens, Elizabeth H. Stover, Nicole Mentens, Helen Van Miegroet, Werner Scheers, Marc Boogaerts, Peter Vandenberghe, Peter Marynen, Jan Cools

Blood (2006) 108 (4): 1374–1376.

https://doi.org/10.1182/blood-2006-02-004457

Published: 2006

Journal Articles

Juxtamembrane Domain Truncation Is Sufficient for Activation of the FIP1L1-PDGFRα and ETV6-PDGFRβ Fusion Kinases.

Elizabeth H. Stover, BA, Jing Chen, PhD, Cedric Folens, Benjamin H. Lee, MD, PhD, Nicole Mentens, Peter Marynen, PhD, D. Gary Gilliland, PhD, MD, Jan Cools, PhD

Blood (2005) 106 (11): 3511.

https://doi.org/10.1182/blood.V106.11.3511.3511

Published: 2005

Journal Articles

Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32)

Kim De Keersmaecker, Carlos Graux, Maria D. Odero, Nicole Mentens, Riet Somers, Johan Maertens, Iwona Wlodarska, Peter Vandenberghe, Anne Hagemeijer, Peter Marynen, Jan Cools

Blood (2005) 105 (12): 4849–4852.

https://doi.org/10.1182/blood-2004-12-4897

Published: 2005

Journal Articles

Fusion of NUP214 to ABL1 on Amplified Extrachromosomal Elements in T-ALL.

Blood (2004) 104 (11): 141.

https://doi.org/10.1182/blood.V104.11.141.141

Published: 2004

Journal Articles

Evidence for position effects as a variant ETV6 -mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13)

Jan Cools, Nicole Mentens, Maria D. Odero, Pieter Peeters, Iwona Wlodarska, Michel Delforge, Anne Hagemeijer, Peter Marynen

Blood (2002) 99 (5): 1776–1784.

https://doi.org/10.1182/blood.V99.5.1776

Published: 2002

NARROW

Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T-cell lymphoma

Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia

JAK3 Mutants Transform Hematopoietic Cells through JAK1 Activation Causing T-Cell Acute Lymphoblastic Leukemia in a Bone Marrow Transplant Mouse Model

Use of Crispr/Cas Genome Editing in Ba/F3 Cells to Generate the Fip1l1-Pdgfra and Nup214-Abl1 Fusion Genes

Synergism Between HOXA9 and Mutant JAK3 (M511I) Leads to Rapid Leukemia Development within an in Vivo Murine Bone Marrow Transplant Model

JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model

PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia

Deletion of the Protein Tyrosine Phosphatase Gene PTPN2 in T-Cell Acute Lymphoblastic Leukemia.

Sorafenib Potently Inhibits ETV6-PDGFRβ and FLT3 Mutants, and Shows Activity Against FLT3 Mutants That Are Resistant to Other Small Molecule Inhibitors.

Oncogenic Properties of the T-ALL Associated EML1-ABL1 and NUP214-ABL1 Fusion Proteins.

Array-CGH Analysis of T-ALL Patients and Cell Lines.

Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant

Juxtamembrane Domain Truncation Is Sufficient for Activation of the FIP1L1-PDGFRα and ETV6-PDGFRβ Fusion Kinases.

Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32)

Fusion of NUP214 to ABL1 on Amplified Extrachromosomal Elements in T-ALL.

Evidence for position effects as a variant ETV6 -mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only